News

Biotech Startup Lyra Therapeutics Brings On First Full-Time CFO Amid Funding Push

 


The Wall Street Journal | September 10, 2019


 

The Wall Street Journal article, “Biotech Startup Lyra Therapeutics Brings On First Full-Time CFO Amid Funding Push," quoted Russell Reynolds Associates Consultant Jenna Fisher on her observations of startup CFO trends. The article is excerpted below.

Lyra Therapeutics Inc., coming off a growth year following an infusion of venture capital, recently hired its first full-time, in-house finance chief—a sign of maturity as the company’s lead medical treatment inches closer to commercialization.

Watertown, Mass.-based Lyra appointed R. Don Elsey as finance chief to help lead the biotechnology company as it goes through rounds of clinical trials for a chronic sinusitis treatment it is developing.

The move to hire a permanent finance chief follows a period during which Lyra employed a string of part-time, contracted finance executives, some outsourced from finance support and CFO services firm Danforth Advisors LLC.

Young, private companies frequently turn to rent-a-CFOs for technical expertise, executive recruiters say. Companies generally outgrow interim and part-time CFOs when revenue exceeds $40 million or, if not yet public, they have a two-year horizon for an initial public offering, said Jenna Fisher, global head of the CFO practice at executive recruiting firm Russell Reynolds Associates.

Hiring a full-time CFO can be a signal of stability and perhaps a sign that a company is ready to take on a new chapter.

To read the full article, click here.


Sign up for our newsletter

Get the newsletter that prepares you for what's next with valuable insights across industries and geographies.
Biotech Startup Lyra Therapeutics Brings On First Full-Time CFO Amid Funding Push